Important pharmacy news and late-breaking industry information updated daily.

The World Health Organization (WHO) has given a name to the illness caused by the new coronavirus: CoViD-19. The name stands for coronavirus disease 2019, the year when the illness was first detected.

The Trump administration's 2021 budget request delivered Monday to Congress includes a nearly 10% cut to HHS, although the requested cuts are not expected to win approval from the House of Representatives, which has the power of the purse and a Democratic majority. The budget request would trim funding for CDC by almost 16%.

On Monday, February 10, CDC released a FAQ resource on shared clinical decision-making recommendations. Access the FAQs at https://apha.us/ACIPfaqs.

A large-scale study of dental visits resulting in opioid prescriptions found that opioid overprescribing by dentists is common. Study results, published in the American Journal of Preventive Medicine, indicate that more than one-half of opioid prescriptions written by dentists exceed the 3-day supply recommended by CDC in its 2016 guidelines for acute dental pain management.

HHS says the U.S. government plans to spend up to $66 million in its initial response to the new coronavirus (2019-nCoV).

Toxicologists, health care practitioners, and others are noticing an alarming trend as physicians have begun prescribing fewer opioids: Gabapentin prescriptions and subsequent misuse of the painkiller have increased.

According to a new survey release February 6 from the National Community Pharmacists Association (NCPA), pharmacists seem split on how big a threat the new coronavirus is to the public. However, it’s a different story for their patients.

Johnson & Johnson was ordered Thursday to pay $750 million in punitive damages to four people who claimed the company's talcum powders caused mesothelioma. Citing state law, however, the judge in the trial, Ana C.

CMS on Wednesday issued a proposed rule to modernize the Medicare Advantage and Part D prescription drug programs as part of an effort to lower beneficiary cost sharing on some of the most expensive prescription drugs, promote the use of generic drugs, and allow beneficiaries to know in advance and compare their out-of-pocket payments for different

HHS announced Tuesday that it is working with Regeneron Pharmaceuticals to develop treatments for the 2019 novel coronavirus (2019-nCoV). The move expands an existing collaboration between the two parties.